Sudan Ebolavirus: The Deadly Strain Without an Approved Vaccine
Sudan ebolavirus has caused 7 outbreaks and killed hundreds of people — yet no approved vaccine or treatment exists. This article examines the threat, the 2022 Uganda outbreak, and the race to develop countermeasures.
A Forgotten Threat That Keeps Returning
When most people hear “Ebola vaccine,” they assume it means protection from all forms of Ebola. It does not. The rVSV-ZEBOV (Ervebo) vaccine — the only widely deployed Ebola vaccine — protects exclusively against Zaire ebolavirus. It provides no meaningful protection against Sudan ebolavirus, the second most prevalent and second most lethal species.
This gap was starkly exposed by the 2022 Uganda Sudan ebolavirus outbreak — the largest Sudan strain outbreak in 18 years — which killed 55 people in a stable, middle-income country with a functioning health system, and left responders without any approved countermeasure beyond supportive care.
Sudan Ebolavirus: The Basics
Sudan ebolavirus was identified in 1976 — the same year as Zaire ebolavirus, but in a separate, simultaneous outbreak. An outbreak of hemorrhagic fever at a cotton factory in Nzara, in what is now South Sudan, killed 151 of 284 infected people (CFR: 53%). International investigators identified a new filovirus distinct from the strain causing the contemporaneous outbreak in DRC.
Key characteristics vs Zaire ebolavirus:
| Feature | Zaire ebolavirus | Sudan ebolavirus |
|---|---|---|
| CFR (untreated) | 60–90% | 41–65% |
| Approved vaccine | Yes (Ervebo) | No |
| Approved treatment | Yes (Inmazeb, Ebanga) | No |
| Outbreaks since 1976 | 20+ | 7 |
| Geographic focus | Central Africa (DRC) | East Africa (Uganda, South Sudan) |
The Seven Sudan Ebolavirus Outbreaks
1976: Nzara and Maridi, Sudan
Cases: 284 | Deaths: 151 | CFR: 53%
The index case was a storeman at a cotton factory in Nzara, where the virus likely spilled over from an infected animal. The outbreak spread to the town of Maridi, where it amplified significantly in the Maridi Hospital — a pattern of hospital amplification that would be repeated in subsequent outbreaks.
1979: Nzara, Sudan
Cases: 34 | Deaths: 22 | CFR: 65%
The virus returned to Nzara three years later, confirming that the Nzara cotton factory area had persistent exposure risk. This was the last Sudan ebolavirus outbreak for over two decades.
2000–2001: Gulu, Uganda
Cases: 425 | Deaths: 224 | CFR: 53%
The largest Sudan ebolavirus outbreak ever recorded, centered in Gulu, Masindi, and Mbarara districts of Uganda. The outbreak spread primarily through hospital transmission and through traditional funeral practices. International teams deployed, including WHO, CDC, and MSF. Barrier nursing and contact tracing ultimately contained the outbreak after several months.
2004: Yambio, Sudan
Cases: 17 | Deaths: 7 | CFR: 41%
A small outbreak in Yambio (Western Equatoria State, now South Sudan) that was rapidly contained within 30 days — demonstrating improved response capacity compared to earlier outbreaks.
2011: Luwero, Uganda
Cases: 1 | Deaths: 1 | CFR: 100%
A single fatal case, rapidly confirmed and contained with no secondary transmission.
2012: Kibaale, Uganda
Cases: 24 | Deaths: 17 | CFR: 71%
An outbreak in Kibaale District with significant healthcare worker transmission. This outbreak highlighted persistent gaps in infection control infrastructure in rural Ugandan hospitals.
2022: Mubende and Kassanda, Uganda
Cases: 164 | Deaths: 55 | CFR: 34%
The most recent and most consequential Sudan ebolavirus outbreak, with lasting implications for global health security. See full analysis below.
The 2022 Uganda Outbreak: A Turning Point
The 2022 Uganda outbreak was confirmed on September 20, 2022, when the Uganda Ministry of Health announced a Sudan ebolavirus case in Mubende District. Within weeks, the outbreak had spread to Kassanda District and generated significant community transmission.
Why 2022 Was Different
No vaccine: The Zaire-specific Ervebo vaccine, which had dramatically aided the DRC Kivu response, was useless here. For the first time since 2000, Ebola responders faced a significant outbreak with no approved vaccine.
Emergency vaccine trials launched mid-outbreak:
Three vaccine candidates were rushed into evaluation:
- ChAd3-Sudan (Oxford/IAVI): A chimpanzee adenovirus vector vaccine expressing Sudan GP — began clinical trial in Uganda during the outbreak
- GamEvac-Combi (Gamaleya): A heterologous VSV/Ad5 regimen from Russia
- BVRS-GamEvac-Combi: A Gamaleya VSV-based regimen
Unfortunately, the Uganda outbreak was declared over on January 11, 2023 — before any vaccine trial had enrolled enough participants to generate efficacy data. A tragic irony: the very success of the outbreak response (containment in 4 months) prevented the trials from generating the data needed to prove vaccines work.
What Worked Despite No Vaccine
- Aggressive contact tracing (1,000+ contacts monitored)
- Ring surveillance around cases
- Strict hospital infection control
- Safe and dignified burials
- Community engagement and risk communication
Uganda’s strong public health infrastructure, developed through years of EVD experience, was decisive. The same outbreak in a country with less experience might have been far larger.
The Countermeasures Gap: What Exists and What Doesn’t
Experimental Treatments for Sudan
No monoclonal antibodies are FDA-approved for Sudan ebolavirus. Investigational candidates include:
- MABS consortium antibodies: Several monoclonal antibodies targeting Sudan GP in preclinical development
- Broad-spectrum antivirals (remdesivir, favipiravir): Limited or no demonstrated efficacy for Sudan strain specifically
Vaccine Development Pipeline
Post-2022, the Sudan ebolavirus vaccine pipeline accelerated significantly:
- CEPI: Pledged $200M for Sudan ebolavirus vaccine development
- Wellcome Trust: Co-funding for pan-ebolavirus vaccine approaches
- Oxford/IAVI: ChAd3-Sudan in Phase 2 trials as of 2024
- Janssen/J&J: Investigating whether their Ad26/MVA heterologous regimen can be adapted for Sudan strain
As of 2026, no Sudan ebolavirus vaccine has completed Phase 3 trials. Emergency Use Authorisation criteria are being prepared for the most advanced candidates so they can be deployed in the next outbreak without waiting for full trials.
The Geographic Threat: East African Vulnerability
Sudan ebolavirus outbreaks have been concentrated in Uganda and South Sudan — but Uganda’s connections to Kenya, Tanzania, Rwanda, and the broader East Africa Community make it a high-risk node. The 2022 outbreak in Mubende — within 150 km of Kampala, the second-largest city in East Africa — demonstrated that Sudan ebolavirus could, in a worse scenario, reach a major urban centre.
What Needs to Happen
The global health community learned hard lessons from the 2022 Uganda outbreak:
- Emergency use frameworks for Sudan ebolavirus vaccines must be pre-negotiated before the next outbreak
- Stockpiling of experimental vaccines in WHO-managed repositories (even without full licensure) for immediate deployment
- Adaptive trial designs that can generate efficacy evidence from smaller, shorter outbreaks
- Pan-ebolavirus vaccine research targeting common GP epitopes shared across all species
The Sudan ebolavirus threat has not diminished. It is likely only a matter of time before the next outbreak, and the world is still inadequately prepared.